EASE SBS-1 measured whether glepaglutide reduced parenteral support needs in people with short bowel syndrome and intestinal failure. Its assigned regimens did not produce identical results: the twice-weekly group showed a significant primary comparison, while the once-weekly group did not. That difference belongs in the summary. A general statement that glepaglutide reduced support can otherwise hide which experimental condition supplied the evidence.

The trial was about support needs in intestinal failure

The 2025 EASE SBS-1 publication describes a randomized, double-blind, placebo-controlled trial in people with short bowel syndrome requiring parenteral support at least three days a week. It compared once-weekly and twice-weekly study schedules over 24 weeks.

That is a narrowly defined clinical question. It is not a study of general digestive wellness, and the schedules identify experimental arms rather than a self-use instruction. The teduglutide guide explains why the amount and type of support are central to interpreting GLP-2 research.

Do not merge two experimental arms into one conclusion

A trial with more than one active schedule can produce different findings for each. The publication reports a significant support reduction for the twice-weekly arm relative to placebo. A summary should preserve the actual arm comparison instead of describing every studied schedule as equally successful.

Scroll horizontally to read all columns.

Record itemQuestion for the reader
Assigned armWhich intervention does this result describe?
Placebo contrastWhat changed beyond background study effects?
Absolute support volumeHow large was the practical change?
Relative reductionHow did change relate to starting requirements?
AutonomyDid any participant become independent of support?

Combining arms after the fact can conceal differences that the original design intended to test.

Why the placebo group may also improve

Participants can experience changes during a trial because of background care, support optimization, observation and other factors. This is precisely why the comparison matters. Reporting only the active arm's before-and-after change overstates what can be assigned to the intervention.

For a volume endpoint, examine whether the same assessment rules were applied to all groups and whether baseline requirements were stabilized. These features help distinguish an intervention effect from changes in clinical management. A protocol-defined support outcome can be clinically useful while still requiring careful interpretation.

Anatomy and baseline burden change the practical meaning

People with a colon in continuity and people with a stoma do not necessarily have the same starting anatomy or support pattern. A proportional change can therefore have different daily implications. Check whether the publication describes these subgroups and whether the study was designed to estimate subgroup differences precisely.

Consider a purely illustrative comparison: reducing a large weekly support volume by one quarter and reducing a small volume by one quarter are the same relative percentage, but not the same absolute volume. Neither tells you the number of infusion-free days unless those days were measured separately.

What the participant interviews add

The later EASE SBS-1 interview publication describes participant-reported experiences of support changes. Such accounts can help explain why an endpoint matters: less support may affect scheduling, freedom or perceived treatment burden. They can complement the randomized endpoint without replacing it.

Interview participants are a selected group, and their accounts should not be treated as a population-wide estimate of benefit. Check selection, timing and the questions asked. A meaningful personal account and a precise comparative effect estimate are different kinds of evidence, each with a useful role.

How a patient account complements a randomized endpoint

A participant may describe being able to plan an activity more easily after a change in support. That account can explain why a volume or scheduling endpoint matters. It does not, by itself, establish how often that experience occurs across all participants or how much is attributable to the assigned intervention.

The randomized comparison and the interview analysis therefore belong next to each other rather than in competition. One estimates a defined group contrast under a protocol; the other explores selected experiences in more detail. The reader should know who was interviewed and how those participants were selected.

Combining the sources responsibly means reporting the trial outcome first, then describing the interview findings with their own limitations. A favorable quotation should not replace an uncertain numerical result, and an average numerical result should not be assumed to capture every aspect of an individual's treatment burden. The clinical endpoint guide explains how to keep these outcome categories distinct.

Keep the randomized groups separate through the conclusion

The phase 3 trial assigned participants to two glepaglutide regimens or placebo. The primary outcome concerned weekly support-volume change at week 24. The twice-weekly group’s favorable result should remain attached to that group, while the once-weekly group’s non-significant primary and key secondary comparisons should remain visible.

Pooling the active groups into one headline would answer a different question from the reported regimen-specific comparisons. It could also hide a result important to development: the nominal molecular identity did not make every assigned exposure schedule equally supported by the trial.

Volume, support days and autonomy have different denominators

The primary mean volume change describes the amount of support over a week. A clinical-response threshold identifies people meeting a defined reduction criterion. A reduction in support days addresses the weekly schedule. Enteral autonomy concerns independence. A participant can meet one without meeting all the others.

Baseline support needs help interpret the burden. An absolute reduction can be meaningful while leaving continued dependence. Conversely, a day off support can affect daily life in a way not captured by liters alone. Those outcomes complement rather than replace each other.

What the exit interviews add

The later interview study explored experiences among a subset of trial participants. It described how support changes affected perceived freedom, sleep and other aspects of life. That provides context a volume table cannot supply, while its small descriptive sample limits the certainty of broad comparative claims.

The interview sample is not a second independent randomized efficacy trial. Participation, recall and the qualitative method need to be considered. A patient account can explain why a measured reduction mattered without estimating the same effect as the main randomized endpoint.

A complete reading therefore combines three records without merging them: the randomized regimen comparison, the support-related secondary outcomes and the descriptive experience study. The teduglutide article and STARS article address related interventions with their own protocols. None supplies a self-directed support-reduction procedure.

What a responsible glepaglutide summary should say

Identify the GLP-2 analogue, intestinal-failure population, 24-week design, specific arm, comparator and support endpoint. Include adverse events and uncertainty, then label the interview findings as a separate source. This produces a much clearer account than saying that a longer-acting peptide is automatically more effective.

Compare with apraglutide STARS evidence only after aligning anatomy, baseline support and assessment rules. The GATTEX label can provide established product context, but it cannot establish regulatory status or clinical equivalence for a different molecule.